Comparative Pharmacology
Head-to-head clinical analysis: GENVOYA versus STRIBILD.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GENVOYA versus STRIBILD.
GENVOYA vs STRIBILD
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Genvoya is a fixed-dose combination of elvitegravir (integrase strand transfer inhibitor), cobicistat (CYP3A inhibitor), emtricitabine (nucleoside reverse transcriptase inhibitor), and tenofovir alafenamide (nucleotide reverse transcriptase inhibitor). Elvitegravir inhibits HIV integrase, blocking viral DNA integration. Emtricitabine and tenofovir alafenamide inhibit HIV reverse transcriptase. Cobicistat boosts elvitegravir levels by inhibiting CYP3A.
STRIBILD is a fixed-dose combination of elvitegravir (integrase strand transfer inhibitor), cobicistat (CYP3A inhibitor to boost elvitegravir), emtricitabine (nucleoside reverse transcriptase inhibitor), and tenofovir disoproxil fumarate (nucleotide reverse transcriptase inhibitor). Elvitegravir inhibits HIV-1 integrase, blocking integration of viral DNA into host genome. Emtricitabine and tenofovir inhibit HIV-1 reverse transcriptase.
One tablet (150 mg elvitegravir, 150 mg cobicistat, 200 mg emtricitabine, 300 mg tenofovir alafenamide) orally once daily with food.
One tablet (150 mg elvitegravir, 150 mg cobicistat, 200 mg emtricitabine, 300 mg tenofovir disoproxil fumarate) orally once daily with food.
None Documented
None Documented
Elvitegravir: 12.9 h; Cobicistat: 3.5 h; Emtricitabine: 10 h (prolonged in renal impairment); Tenofovir alafenamide: 0.5 h (but intracellular tenofovir-diphosphate half-life >60 h). Effective dosing interval: 24 h
Elvitegravir: 12.9 h (boosted by cobicistat). Cobicistat: 3-4 h. Emtricitabine: 10 h. Tenofovir: 12-18 h (prolonged in renal impairment). Clinical context: Once-daily dosing maintains therapeutic concentrations.
Elvitegravir: 94.8% fecal, 6.7% renal; Cobicistat: 86.2% fecal, 8.2% renal; Emtricitabine: 70% renal (active tubular secretion); Tenofovir alafenamide: <1% renal, >80% fecal as tenofovir
Elvitegravir: 94.8% in feces (parent drug and metabolites), 6.7% in urine. Cobicistat: 86.2% in feces, 8.2% in urine. Emtricitabine: 86% in urine (70% unchanged), 14% in feces. Tenofovir: 70-80% in urine (unchanged) via glomerular filtration and active tubular secretion.
Category C
Category C
Antiretroviral Combination
Antiretroviral Combination